Author: digi

Real-World Evidence (RWE) Generation from Phase 4 Trials

June 10, 2025

Real-World Evidence (RWE) Generation from Phase 4 Trials Generating High-Impact Real-World Evidence from Phase 4 Clinical Trials Introduction Real-World Evidence (RWE) has emerged as a powerful supplement to traditional clinical trial data, especially in Phase 4 trials. Generated from everyday patient experiences and routine care, RWE provides actionable insights that inform healthcare decisions, payer coverage,…

Phase 4 (Post-Marketing Surveillance)

What is a Full-Service CRO in Clinical Trials? Explained with Services and Best Practices

June 10, 2025

digi

What is a Full-Service CRO in Clinical Trials? Explained with Services and Best Practices Understanding the Role and Scope of Full-Service CROs in Clinical Trials As the complexity and scale of drug development have increased, pharmaceutical companies have increasingly turned to Contract Research Organizations (CROs) to streamline the clinical trial process. Among them, the full-service…

Contract Research Organizations (CROs), Full-Service CROs

Feasibility Metrics for Selecting Trial Sites in Clinical Research

June 10, 2025

digi

Essential Feasibility Metrics for Selecting the Right Clinical Trial Sites Choosing the right investigational sites is one of the most critical factors influencing the success of a clinical trial. Site feasibility assessments go beyond basic questionnaires—they require evaluating robust metrics that predict a site’s ability to deliver high-quality data, recruit effectively, and meet regulatory standards….

Site Feasibility Assessments, Site Management and Monitoring

Using External and Historical Controls in Phase 2 Trials

June 10, 2025

digi

Using External and Historical Controls in Phase 2 Trials Leveraging External and Historical Controls in Phase 2 Clinical Trial Designs Introduction In certain therapeutic areas—especially rare diseases, oncology, and life-threatening conditions—randomized controlled trials may be impractical or ethically challenging in Phase 2. In such cases, researchers may use external or historical controls to assess treatment…

Phase 2 (Efficacy and Side Effects)

Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies

June 10, 2025

digi

Protocol Amendment Management in Phase 3 Trials: Impact and Risk Control Strategies Managing Protocol Amendments During Phase 3 Trials: A Practical Guide Understanding Protocol Amendments in Phase 3 Protocol amendments are modifications made to a clinical trial protocol after the trial has started. In Phase 3 trials—where regulatory scrutiny, patient numbers, and operational complexity are…

Phase 3 (Confirmation and Monitoring)

Document Collection Checklist for Study Initiation in Clinical Trials

June 10, 2025

digi

Comprehensive Guide to Document Collection for Clinical Study Initiation Successful clinical study initiation hinges on the timely collection, review, and approval of essential documents. These documents are critical for ensuring GMP compliance, meeting regulatory requirements, and confirming site readiness. This article provides a structured tutorial on the essential documents required during the study start-up phase,…

Clinical Research Operations, Study Start-Up Activities

Setting Up a Remote Patient Monitoring Plan in Decentralized Clinical Trials

June 10, 2025

digi

Setting Up a Remote Patient Monitoring Plan in Decentralized Clinical Trials How to Set Up a Remote Patient Monitoring Plan in Decentralized Clinical Trials Remote Patient Monitoring (RPM) is a fundamental component of Decentralized Clinical Trials (DCTs), enabling continuous data capture and reducing the burden on participants. However, implementing RPM requires a robust, well-documented plan…

Decentralized Clinical Trials (DCTs), Remote Patient Monitoring

Early Termination of Phase 2 Trials: Criteria and Communication

June 10, 2025

digi

Early Termination of Phase 2 Trials: Criteria and Communication When and How to Terminate a Phase 2 Trial Early: Criteria, Ethics, and Communication Strategies Introduction Early termination of a Phase 2 trial—whether due to futility, safety concerns, or overwhelming efficacy—is a critical decision that can impact patients, sponsors, regulators, and future development plans. While stopping…

Phase 2 (Efficacy and Side Effects)

Post-Marketing Commitments and Post-Authorization Safety Studies (PASS)

June 10, 2025

digi

Post-Marketing Commitments and Post-Authorization Safety Studies (PASS) How Phase 4 Commitments and PASS Shape Drug Safety Surveillance Introduction After a medicine enters the market, the need for safety monitoring intensifies—not fades. To ensure ongoing evaluation of benefit-risk balance, regulatory agencies may require pharmaceutical companies to undertake post-marketing commitments (PMCs) and conduct Post-Authorization Safety Studies (PASS)….

Phase 4 (Post-Marketing Surveillance)